Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery


NCT01182272

Interventional

Phase 2

Unknown status
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sorafenib tosylate works in treating patients with liver cancer that can be removed by surgery.
May 31,2010
All
18 Years
N/A
36

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.